Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 5, 2009, Pages 1039-1046

  Takeshita, Takashi ^a   Wu, Wenwen ^a   Koike, Ayaka ^a,b   Fukuda, Mamoru ^a   Ohta, Tomohiko ^a,b  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ST MARIANNA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemosensitivity; DNA damage; Nuclear foci formation; Proteasome inhibitor; Ubiquitin

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DOCETAXEL; EPIRUBICIN; EPOXOMICIN; IRINOTECAN; PACLITAXEL; UBIQUITIN;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOSOL; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENTIATION; FEMALE; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UBIQUITINATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; COMET ASSAY; DNA DAMAGE; DNA REPAIR; EPIRUBICIN; FEMALE; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LEUPEPTINS; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 69049099939     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0961-5     Document Type: Article

References (43)

1. W Sakai EM Swisher BY Karlan MK Agarwal J Higgins C Friedman E Villegas C Jacquemont DJ Farrugia FJ Couch et al. 2008 Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers Nature 451 1116 1120
2. EM Swisher W Sakai BY Karlan K Wurz N Urban T Taniguchi 2008 Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance Cancer Res 68 2581 2586
3. SL Edwards R Brough CJ Lord R Natrajan R Vatcheva DA Levine J Boyd JS Reis-Filho A Ashworth 2008 Resistance to therapy caused by intragenic deletion in BRCA2 Nature 451 1111 1115
4. B Wang SJ Elledge 2007 Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage Proc Natl Acad Sci USA 104 20759 20763
5. N Mailand S Bekker-Jensen H Faustrup F Melander J Bartek C Lukas J Lukas 2007 RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins Cell 131 887 900
6. NK Kolas JR Chapman S Nakada J Ylanko R Chahwan FD Sweeney S Panier M Mendez J Wildenhain TM Thomson et al. 2007 Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase Science 318 1637 1640
7. MS Huen R Grant I Manke K Minn X Yu MB Yaffe J Chen 2007 RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly Cell 131 901 914
8. B Wang S Matsuoka BA Ballif D Zhang A Smogorzewska SP Gygi SJ Elledge 2007 Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response Science 316 1194 1198
9. B Sobhian G Shao DR Lilli AC Culhane LA Moreau B Xia DM Livingston RA Greenberg 2007 RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites Science 316 1198 1202
10. H Kim J Chen X Yu 2007 Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response Science 316 1202 1205
11. R Hashizume M Fukuda I Maeda H Nishikawa D Oyake Y Yabuki H Ogata T Ohta 2001 The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation J Biol Chem 276 14537 14540
12. RA Greenberg B Sobhian S Pathania SB Cantor Y Nakatani DM Livingston 2006 Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes Genes Dev 20 34 46
13. GY Zhao E Sonoda LJ Barber H Oka Y Murakawa K Yamada T Ikura X Wang M Kobayashi K Yamamoto et al. 2007 A critical role for the ubiquitin-conjugating enzyme Ubc13 in initiating homologous recombination Mol Cell 25 663 675
14. A Hershko A Ciechanover 1998 The ubiquitin system Annu Rev Biochem 67 425 479
15. CM Pickart 2001 Ubiquitin enters the new millennium Mol Cell 8 499 504
16. K Tanaka T Chiba 1998 The proteasome: a protein-destroying machine Genes Cells 3 499 510
17. JR Morris E Solomon 2004 BRCA1: BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair Hum Mol Genet 13 807 817
18. NP Dantuma TA Groothuis FA Salomons J Neefjes 2006 A dynamic ubiquitin equilibrium couples proteasomal activity to chromatin remodeling J Cell Biol 173 19 26
19. K Sato R Hayami W Wu T Nishikawa H Nishikawa Y Okuda H Ogata M Fukuda T Ohta 2004 Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase J Biol Chem 279 30919 30922
20. M Hanada K Sugawara K Kaneta S Toda Y Nishiyama K Tomita H Yamamoto M Konishi T Oki 1992 Epoxomicin, a new antitumor agent of microbial origin J Antibiot (Tokyo) 45 1746 1752
21. N Sin KB Kim M Elofsson L Meng H Auth BH Kwok CM Crews 1999 Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology Bioorg Med Chem Lett 9 2283 2288
22. L Meng R Mohan BH Kwok M Elofsson N Sin CM Crews 1999 Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity Proc Natl Acad Sci USA 96 10403 10408
23. LF Liu SD Desai TK Li Y Mao M Sun SP Sim 2000 Mechanism of action of camptothecin Ann N Y Acad Sci 922 1 10
24. T Hideshima P Richardson D Chauhan VJ Palombella PJ Elliott J Adams KC Anderson 2001 The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Res 61 3071 3076
25. PG Richardson B Barlogie J Berenson S Singhal S Jagannath D Irwin SV Rajkumar G Srkalovic M Alsina R Alexanian et al. 2003 A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2609 2617
26. RH Engel JA Brown JH Von Roenn RM O'Regan R Bergan S Badve A Rademaker WJ Gradishar 2007 A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience Cancer Invest 25 733 737
27. CH Yang AM Gonzalez-Angulo JM Reuben DJ Booser L Pusztai S Krishnamurthy D Esseltine J Stec KR Broglio R Islam et al. 2006 Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits Ann Oncol 17 813 817
28. A Awada J Albanell PA Canney LY Dirix T Gil F Cardoso P Gascon MJ Piccart J Baselga 2008 Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study Br J Cancer 98 1500 1507
29. Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D, Orlowski RZ (2008) A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemother Pharmacol [Epub ahead of print]
30. P Schmid D Kuhnhardt P Kiewe S Lehenbauer-Dehm W Schippinger R Greil W Lange J Preiss N Niederle P Brossart et al. 2008 A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines Ann Oncol 19 871 876
31. T Hideshima D Chauhan P Richardson C Mitsiades N Mitsiades T Hayashi N Munshi L Dang A Castro V Palombella et al. 2002 NF-kappa B as a therapeutic target in multiple myeloma J Biol Chem 277 16639 16647
32. N Mitsiades CS Mitsiades PG Richardson V Poulaki YT Tai D Chauhan G Fanourakis X Gu C Bailey M Joseph et al. 2003 The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications Blood 101 2377 2380
33. MK Yunmbam QQ Li EG Mimnaugh GL Kayastha JJ Yu LN Jones L Neckers E Reed 2001 Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells Int J Oncol 19 741 748
34. C Jacquemont T Taniguchi 2007 Proteasome function is required for DNA damage response and fanconi anemia pathway activation Cancer Res 67 7395 7405
35. Y Murakawa E Sonoda LJ Barber W Zeng K Yokomori H Kimura A Niimi A Lehmann GY Zhao H Hochegger et al. 2007 Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells Cancer Res 67 8536 8543
36. J Codony-Servat MA Tapia M Bosch C Oliva J Domingo-Domenech B Mellado M Rolfe JS Ross P Gascon A Rovira et al. 2006 Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells Mol Cancer Ther 5 665 675
37. CM Perou T Sorlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen et al. 2000 Molecular portraits of human breast tumours Nature 406 747 752
38. T Sorlie R Tibshirani J Parker T Hastie JS Marron A Nobel S Deng H Johnsen R Pesich S Geisler et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 8418 8423
39. TO Nielsen FD Hsu K Jensen M Cheang G Karaca Z Hu T Hernandez-Boussard C Livasy D Cowan L Dressler et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367 5374
40. N Turner A Tutt A Ashworth 2004 Hallmarks of 'BRCAness' in sporadic cancers Nat Rev Cancer 4 814 819
41. A McCarthy K Savage A Gabriel C Naceur JS Reis-Filho A Ashworth 2007 A mouse model of basal-like breast carcinoma with metaplastic elements J Pathol 211 389 398
42. X Liu H Holstege H van der Gulden M Treur-Mulder J Zevenhoven A Velds RM Kerkhoven MH van Vliet LF Wessels JL Peterse et al. 2007 Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer Proc Natl Acad Sci USA 104 12111 12116
43. R Shakya M Szabolcs E McCarthy E Ospina K Basso S Nandula V Murty R Baer T Ludwig 2008 The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression Proc Natl Acad Sci USA 105 19 7040 7045